Incremental PD With Single Icodextrin Exchange

Launched by RENJI HOSPITAL · Nov 2, 2023

Keywords

ClinConnect Summary

This clinical trial is looking at a new way to start peritoneal dialysis (PD), a treatment for people with severe kidney disease. Specifically, it will study the effects of using a solution called icodextrin during a single daily exchange to see if it helps maintain kidney function and overall health better than standard methods. The trial will involve 72 patients who are beginning PD, and researchers will track changes in their kidney function over 48 weeks.

To be eligible for this trial, participants need to be between 18 and 75 years old, have chronic kidney disease stage 5, and still have some urine output. They should also have a certain level of kidney function measured by a test called eGFR. However, people with serious health conditions, allergies to the study solution, or those who are pregnant or breastfeeding cannot participate. The trial is not yet recruiting patients, so there is no need to apply just yet. Participants will receive close monitoring and support throughout the study, helping researchers understand if this new approach to dialysis can improve health outcomes for patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. male or female patients aged 18 to 75 years;
• • 2. patients with chronic kidney disease stage 5 who are to start PD;
• • 3. eGFR ≥ 5 ml/min;
• • 4. urine output ≥ 800 ml/d.
• Exclusion Criteria:
• • 1. documented anaphylaxis with icodextrin or glucose-based dialysate;
• • 2. concomitant severe chronic diseases such as malignancy, hepatitis, severe cardiac diseases, etc.;
• • 3. ongoing severe infection;
• • 4. planned or ongoing pregnancy or lactation;
• • 5. currently enrolled in other clinical studies;
• • 6. patients who have a life expectancy of \<12 months;
• • 7. refusal to give a written consent.